Simple Summary Borderline resectable pancreatic cancer (BRPC) has been primarily
indicated for neoadjuvant treatment (NAT) in the last decade. This study is the updated meta …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. Despite the
development of multimodality treatments, including surgical resection, radiotherapy, and …

Objective: This study investigates the use of serum DUPAN-2 in predicting the PC
progression in CA19-9 nonsecretors. Background: Although we previously reported that …

This is a phase II study of PD-1 blockade plus chemoradiotherapy as preoperative therapy
for patients with locally advanced or borderline resectable pancreatic cancer (LAPC or …

Background Early-onset pancreatic cancer (≤ 50 years, EOPC) is uncommon. This study
aims to characterize the clinical and survival characteristics of EOPC in comparison to late …

Background Previous studies on borderline resectable (BR) pancreatic cancer (PC)
included patients with heterogenous preoperative states; however, the definition of …

Background Patients with pancreatic cancer (PC) have poor prognosis and a high incidence
of recurrence. Since further treatment is applicable for specific recurrent events, it is …

Background Nab‐paclitaxel plus gemcitabine is a standard treatment for metastatic/locally
advanced pancreatic cancer. The effectiveness of neoadjuvant therapy with nab‐paclitaxel …

Background Only two clinical trials have shown the effects of neoadjuvant treatment for
borderline resectable pancreatic cancer with arterial involvement (BRPC-A). Here, we aimed …

Background Although some clinical trials have demonstrated the benefits of neoadjuvant
therapy for resectable pancreatic ductal adenocarcinoma (PDAC), its optimal candidate has …